J. Goldman & Co’s Cartesian Therapeutics RNAC Stock Holding History

J. Goldman & Co’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-956	Closed	-$69K	–	328
2020 Q1	$69K	Buy	+956	New	+$92.3K	0.01%	228

Other funds holding RNAC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

J. Goldman & Co's RNAC Position: Q2 2020 in Review

J. Goldman & Co sold out of Cartesian Therapeutics (RNAC) in Q2 2020, closing a stake of 956 shares — an estimated $69K sold.

J. Goldman & Co first reported a position in RNAC in Q1 2020 and held it in 1 quarter. The position peaked at $69K in Q1 2020. 81 funds tracked by Wall St. Rank hold RNAC as of Q2 2020.

J. Goldman & Co reported no remaining Cartesian Therapeutics position as of Q2 2020 after selling out during the quarter.
J. Goldman & Co sold 956 Cartesian Therapeutics shares in Q2 2020, an estimated $69K.
J. Goldman & Co first reported a position in Cartesian Therapeutics in Q1 2020 and held it in 1 quarter.
J. Goldman & Co's Cartesian Therapeutics position peaked at $69K in Q1 2020.
81 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2020.

Based on J. Goldman & Co's 13F filing for Q2 2020, filed 14 Aug 2020.